Dupilumab for the Treatment of Atopic Dermatitis.

Dupilumab for the Treatment of Atopic Dermatitis.
Actas Dermosifiliogr. 2018 Feb 05;:
Authors: Ferreira S, Torres T
Abstract
Atopic dermatitis (AD) is a common, chronic, inflammatory skin disorder with high physical and emotional burden. AD usually starts in early childhood and has a heterogeneous course. Emerging evidence suggests that IL-4 and IL-13 are key cytokines in the immunopathogenesis of AD. Dupilumab is a monoclonal antibody directed against IL-4 receptor α subunit, that blocks both IL-4 and IL-13 signaling. Data from Phase I-III studies revealed that dupilumab, administered as monotherapy or with topical corticosteroids, is effective and well tolerated in the treatment of adult patients with moderate-to-severe AD. A large proportion of patients receiving dupilumab had significant improvements in multiple efficacy indexes, including Eczema Area and Severity Index, Investigator's Global Assessment and SCORing Atopic Dermatitis scores. These results introduce a new era of targeted therapies in the management of AD.
PMID: 29422431 [PubMed - as supplied by publisher]

Source: Actas Dermo-Sifiliograficas - February 5, 2018 Category: Dermatology Authors: Ferreira S, Torres T Tags: Actas Dermosifiliogr Source Type: research